Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - CymaBay Therapeutics, Inc. | d41924dex321.htm |
| EX-31.2 - EX-31.2 - CymaBay Therapeutics, Inc. | d41924dex312.htm |
| EX-31.1 - EX-31.1 - CymaBay Therapeutics, Inc. | d41924dex311.htm |
| EX-21.1 - EX-21.1 - CymaBay Therapeutics, Inc. | d41924dex211.htm |
| EX-10.18 - EX-10.18 - CymaBay Therapeutics, Inc. | d41924dex1018.htm |
| EX-10.8 - EX-10.8 - CymaBay Therapeutics, Inc. | d41924dex108.htm |
| EX-10.7 - EX-10.7 - CymaBay Therapeutics, Inc. | d41924dex107.htm |
| EX-4.2 - EX-4.2 - CymaBay Therapeutics, Inc. | d41924dex42.htm |
| 10-K - FORM 10-K - CymaBay Therapeutics, Inc. | d41924d10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-229670) of CymaBay Therapeutics, Inc., and |
| (2) | Registration Statements (Form S-8 Nos. 333-195211, 333-198289, 333-202941, 333-210453, 333-216905, 333-223687, 333-226741, and 333-229953) pertaining to the Metabolex, Inc. 2003 Equity Incentive Plan, and the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan; |
of our report dated March 25, 2021, with respect to the consolidated financial statements of CymaBay Therapeutics, Inc. included in this Annual Report (Form 10-K) of CymaBay Therapeutics, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Redwood City, California
March 25, 2021